<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03789214</url>
  </required_header>
  <id_info>
    <org_study_id>IRB00198426</org_study_id>
    <secondary_id>UG3DA048734</secondary_id>
    <nct_id>NCT03789214</nct_id>
  </id_info>
  <brief_title>Medical Management of Sleep Disturbance During Opioid Tapering</brief_title>
  <official_title>Medical Management of Sleep Disturbance During Opioid Tapering</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Johns Hopkins University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute on Drug Abuse (NIDA)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Johns Hopkins University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate whether a dual orexin-receptor antagonist approved by the FDA for
      sleep disturbance, suvorexant (SUVO; Belsomra), will increase total sleep time in patients
      with opioid use disorder (OUD) undergoing supervised withdrawal. This study is designed as a
      dose-finding study of SUVO compared to placebo. Briefly, OUD patients seeking supervised
      withdrawal will be admitted into a clinical research unit and stabilized onto buprenorphine
      for three days before being randomly assigned to study condition. All participants will then
      undergo a routine four-day buprenorphine taper, followed by a four-day post-taper phase.
      Participants will be randomized to receive either placebo, Low Dose SUVO, or High Dose SUVO
      and the investigators hypothesize that one or both doses of SUVO will improve total sleep
      time relative to placebo. Patients will attend a single follow-up session, 5-10 days
      following discharge.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 1, 2019</start_date>
  <completion_date type="Anticipated">July 2021</completion_date>
  <primary_completion_date type="Anticipated">July 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Total Sleep Time</measure>
    <time_frame>8 nights</time_frame>
    <description>Area-under-the-curve scores of total number of minutes slept per night as measured by a 3-lead wireless electroencephalography and wrist worn actigraphy. Area-under-the-curve scores will represent two time frames: (1) four nights during an opioid taper, and (2) four nights post taper.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Subjective Opiate Withdrawal Scale (SOWS)</measure>
    <time_frame>6 days</time_frame>
    <description>Area-under-the-curve of peak daily scores on the SOWS (a 16-item self-reported scale that measures individual opioid withdrawal symptoms using a 0-4 Likert scale; total range of SOWS is 0-64; lower scores indicate mild opioid withdrawal relative to higher scores which indicate more severe opioid withdrawal). Area-under-the-curve scores will represent two time frames: (1) three days during an opioid taper, and (2) three days post taper.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Abuse Liability as assessed by visual analogue scale</measure>
    <time_frame>4 nights</time_frame>
    <description>Area-under-the-curve of self-reported feelings of drug &quot;High&quot; on the morning after study drug administration, measured each morning on a 0-100 point visual analogue scale of the question &quot;Last night, did you feel HIGH?&quot;. A score of &quot;0&quot; indicates no abuse liability and a score of 100 indicates extreme abuse liability. This will be assessed over four nights during an opioid taper.</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">45</enrollment>
  <condition>Opioid Dependence</condition>
  <condition>Opioid Withdrawal</condition>
  <condition>Sleep Disturbance</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo sleep medication (Placebo oral capsule)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Low Dose Suvorexant</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Low dose sleep medication</description>
  </arm_group>
  <arm_group>
    <arm_group_label>High Dose Suvorexant</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>High dose sleep medication</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo oral capsule</intervention_name>
    <description>Placebo Sleep Medication</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Low Dose Suvorexant</intervention_name>
    <description>Low Dose Suvorexant</description>
    <arm_group_label>Low Dose Suvorexant</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>High Dose Suvorexant</intervention_name>
    <description>High Dose Suvorexant</description>
    <arm_group_label>High Dose Suvorexant</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Aged 18 years old and above

          -  Meets Diagnostic and Statistical Manual of Mental Disorders (DSM)-5 criteria for OUD
             with evidence of physical dependence on opioids, and seeking treatment to stop using
             illicit opioids.

          -  Provides a urine sample that tests positive for opioids.

          -  Willing to comply with the study protocol.

          -  Have no clinically significant chronic medical or surgical disorders or conditions
             that are judged by the investigators to prevent participation.

        Exclusion Criteria:

          -  Seeking or currently enrolled in methadone or buprenorphine maintenance treatment for
             OUD

          -  Pregnant or breast feeding

          -  Have evidence of physical dependence on alcohol or benzodiazepines that requires
             medical detoxification

          -  Have a known allergy to the study medications

          -  Past 30-day prescribed use of suvorexant or benzodiazepines for the indication of
             insomnia

          -  Current use of a Selective Serotonin Reuptake Inhibitor (SSRI) or Monoamine oxidase
             (MAO) inhibitor for depression or insomnia, or other medications that are
             contraindicated with suvorexant

          -  Current narcolepsy, restless leg syndrome or sleep paralysis

          -  High risk for current sleep apnea

          -  Current major depressive disorder

          -  Past year suicidal behavior

          -  Severe hepatic or renal impairment

               -  Aspartate aminotransferase (AST) or Alanine aminotransferase (ALT) &gt;3x ULN

               -  Total bilirubin &gt;2x Upper Limit of Normal (ULN)

               -  Creatinine &gt;1.5x ULN

          -  Have circumstances that would interfere with study participation (e.g., impending
             jail)
      </textblock>
    </criteria>
    <gender>All</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Self-reported male or female</gender_description>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Andrew S Huhn, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Johns Hopkins University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Andrew S Huhn, PhD</last_name>
    <phone>410-550-1971</phone>
    <email>ahuhn1@jhu.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Kelly E Dunn, PhD</last_name>
    <phone>410-550-2254</phone>
    <email>kdunn9@jhmi.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Johns Hopkins Bayview Medical Center</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21224</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andrew S Huhn, PhD</last_name>
      <phone>410-550-1971</phone>
      <email>ahuhn1@jhu.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>December 26, 2018</study_first_submitted>
  <study_first_submitted_qc>December 26, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">December 28, 2018</study_first_posted>
  <last_update_submitted>July 8, 2020</last_update_submitted>
  <last_update_submitted_qc>July 8, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 9, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dyssomnias</mesh_term>
    <mesh_term>Parasomnias</mesh_term>
    <mesh_term>Opioid-Related Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Suvorexant</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

